Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 153

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 8
Chunk 153
---
,863 $12,259 Impact of foreign currency fluctuations(73)Total net sales12,186 Segment expenses:Cost of products sold1,193 27.1 %2,500 31.8 %3,694 Selling, general and administrative expenses1,334 30.3 %2,327 29.6 %3,661 Research and development expenses335 7.6 %703 8.9 %1,038 Other segment items(1)9 0.2 %14 0.2 %23 Segment operating income(2)1,525 34.7 %2,318 29.5 %3,843 Unallocated amounts:Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(565)Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(719)Amortization expense(631)Operating income (loss) 1,928 Other income (expense), net(231)Income (loss) before income taxes$1,697 (1) Includes royalty expense.(2) Calculated as Net sales of reportable segments less Segment expenses. Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Depreciation expense (in millions)2025202420252024MedSurg$29 $27 $84 $79 Cardiovascular89 75 250 211 Consolidated depreciation expense$117 $102 $334 $290 As ofTotal assets (in millions)September 30, 2025December 31, 2024MedSurg$3,392 $3,093 Cardiovascular7,799 7,084 Total assets of reportable segments11,191 10,177 Goodwill18,214 17,089 Other intangible assets, net7,162 6,684 All other corporate assets6,140 5,446  $42,707 $39,395 

35

Table of Contents

As ofLong-lived assets (in millions)September 30, 2025December 31, 2024U.S.$1,812 $1,461 Ireland707 631